Clinical Trials Browser

Phase 1/2 × Leukemia × acalabrutinib × Clear all

NCT07052695 2025-12-15

Mosunetuzumab for CLL MRD Clearance

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04961801 2022-03-08

Acalabrutinib for GVHD Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and Leukemia

Phase 1/2 Withdrawn

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma